The Egyptian International Pharmaceutical Industries Company (EIPICO) has started production of (Epifluver – Favipiravir 200 mg), used in the treatment of the novel coronavirus (COVID-19).
The production of the drug comes after EIPICO received approval from the Egyptian Drug Authority (EDA).
In a statement from the company, EIPICO said in a statement that the antiviral was approved for use, as part of the treatment protocol for the coronavirus, in Russia and China. The Egyptian company said that it has started manufacturing of the drug following the EDA approval, and will soon begin manufacturing Remdesivir, which is also used to treat the novel virus.
EIPICO Chairperson and Managing Director, Ahmed El-Kilany, said the company has, by mid-July, produced as much as 16m packs of drugs used by the Ministry of Health to combat the coronavirus.
The company currently also produces drugs such as Paracetamol, ampoules of anti-inflammatory drug dexamethasone, epithromycin antibiotics, vitamins, and immune-enhancing drugs, as well as Vitamin C and zinc tablets.